Denosumab safe and effective in chronic liver disease patients with osteoporosis

Key clinical point: Denosumab treatment was safe and increased bone mineral density (BMD), suppressed bone turnover, and improved bone quality marker levels in chronic liver disease (CLD) patients with osteoporosis.

Major finding: At 12 months, denosumab significantly improved BMD at the lumbar spine, femoral neck, and total hip regardless of age, gender, and presence/absence of liver cirrhosis (+4.44%, +3.71%, and +4.03%, respectively; P less than .001 for all). Denosumab significantly decreased serum levels of tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide (P less than .001 for both) and also plasma pentosidine level (P = .010). No patients experienced fractures and moderate-to-severe adverse events, except for transient hypocalcemia.

Study details: The data come from a retrospective study of 60 CLD patients with osteoporosis who were subcutaneously administered denosumab once every 6 months.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Saeki C et al. World J Gastroenterol. 2020 Sep 7. doi: 10.3748/wjg.v26.i33.4960.

Key clinical point: Denosumab treatment was safe and increased bone mineral density (BMD), suppressed bone turnover, and improved bone quality marker levels in chronic liver disease (CLD) patients with osteoporosis.

Major finding: At 12 months, denosumab significantly improved BMD at the lumbar spine, femoral neck, and total hip regardless of age, gender, and presence/absence of liver cirrhosis (+4.44%, +3.71%, and +4.03%, respectively; P less than .001 for all). Denosumab significantly decreased serum levels of tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide (P less than .001 for both) and also plasma pentosidine level (P = .010). No patients experienced fractures and moderate-to-severe adverse events, except for transient hypocalcemia.

Study details: The data come from a retrospective study of 60 CLD patients with osteoporosis who were subcutaneously administered denosumab once every 6 months.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Saeki C et al. World J Gastroenterol. 2020 Sep 7. doi: 10.3748/wjg.v26.i33.4960.

Key clinical point: Denosumab treatment was safe and increased bone mineral density (BMD), suppressed bone turnover, and improved bone quality marker levels in chronic liver disease (CLD) patients with osteoporosis.

Major finding: At 12 months, denosumab significantly improved BMD at the lumbar spine, femoral neck, and total hip regardless of age, gender, and presence/absence of liver cirrhosis (+4.44%, +3.71%, and +4.03%, respectively; P less than .001 for all). Denosumab significantly decreased serum levels of tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide (P less than .001 for both) and also plasma pentosidine level (P = .010). No patients experienced fractures and moderate-to-severe adverse events, except for transient hypocalcemia.

Study details: The data come from a retrospective study of 60 CLD patients with osteoporosis who were subcutaneously administered denosumab once every 6 months.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Saeki C et al. World J Gastroenterol. 2020 Sep 7. doi: 10.3748/wjg.v26.i33.4960.